Almirall, S.A. (LBTSF.PK), a biopharmaceutical company, on Monday reported higher profit for the first nine months of 2025, mainly driven by growth in sales.
Net income for the 9-month period surged to €39.1 million from €7.2 million in the same period last year.
EBITDA, or earnings before interest, taxes, depreciation, and amortization rose 27.1% year-on-year to €180.7 million.
Revenue increased 12.9% to €825.6 million from €731.2 million last year, with net sales growth of 12.8% to €820.7 million.
For the full year 2025, the company continues to expect net sales growth of between 10% and 13%, and EBITDA in the range of €220 million to €240 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.